ATZUMI (DIHYDROERGOTAMINE MESYLATE)
ATZUMI (DIHYDROERGOTAMINE MESYLATE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: ATZUMI; Generic name: DIHYDROERGOTAMINE MESYLATE; Manufacturer: Satsuma Pharmaceuticals, Inc..
| Brand name | ATZUMI |
|---|---|
| Generic name | DIHYDROERGOTAMINE MESYLATE |
| Manufacturer | Satsuma Pharmaceuticals, Inc. |
| Used for | 1 INDICATIONS AND USAGE ATZUMI is indicated for the acute treatment of migraine with or without aura in adults. ATZUMI is an ergotamine derivative indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use ATZUMI is not indicated for the preventive treatment of migraine or for the management of hemiplegic migraine or migraine with brainstem aura. ( 1 ) Limitations of Use ATZUMI is not indicated for the preventive treatment of migraine. ATZUMI is not indicated for the management of hemiplegic migraine or migraine with brainstem aura. |
| Dosage | 2 DOSAGE AND ADMINISTRATION ATZUMI is for nasal administration only. ( 2.1 ) The recommended dose of ATZUMI is 5.2 mg, the contents of one nasal device, administered into one nostril. ( 2.1 ) To administer a dose, the white air pump of the ATZUMI device must be squeezed three separate times into one nostril. ( 2.1 ) The dose may be repeated, if needed, a minimum of 1 hour after the first dose. The maximum dose in a 24-hour period is 10.4 mg (two doses of ATZUMI 5.2 mg). ( 2.1 ) The safety of tak |
| Warnings | WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH STRONG CYP3A4 INHIBITORS Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with strong CYP3A4 inhibitors. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of ATZUMI with strong CYP3A4 inhibitors is contraindicated [see Co |
| Active ingredient(s) | DIHYDROERGOTAMINE MESYLATE |
| Route | NASAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0982a44a-dc0c-75c0-e063-6394a90a6d6c |